Get started
Author

María Jesús Rubio

Observed names: Maria Jesús Rubio, Rubio, Maria Jesus, Rubio, María Jesús
OpenAlex ID: A5113035509
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial
2024 · Mansoor R. Mirza, Line Bjørge, et al. · Gynecologic Oncology · 35
PDF
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al. · Clinical Cancer Research · 34
PDF
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
2025 · Ana Oaknin, Bradley J. Monk, et al. · European Journal of Cancer · 32
Pembrolizumab Or Placebo Plus Adjuvant Chemotherapy With Or Without Radiotherapy In Patients With Newly Diagnosed, High-Risk Endometrial Cancer: Exploratory Analysis Of Disease-Specific Survival From The Phase 3 ENGOT-En11/GOG-3053/KEYNOTE-B21 Study
2025 · Michael J. Halaska, Toon Van Gorp, et al. · International Journal of Gynecological Cancer · 2
PDF
#525 Impact of BRCA mutation status on efficacy of atezolizumab combined with platinum-based chemotherapy and maintenance niraparib for late-relapsing recurrent ovarian cancer: subgroup analysis of the ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial
2024 · Frédéric Selle, Maria Jesús Rubio, et al. · International Journal of Gynecological Cancer · 2
Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
PDF
Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
PDF
Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Five Years Of Real-Life Data In Gynaecological Cancers: A Multicenter Clinical Registry With Associated Samples (GEICO 81-T)
2025 · Fernando Gálvez, Gloria Marquina, et al. · International Journal of Gynecological Cancer
Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Works count: 39
Citation count: 105
H-index: 3
I10-index: 3
Year
Topic
Type